The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid

Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid
Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid
Seasonal allergic rhinitis is characterized by the development of nasal mucosal inflammation in response to natural allergen exposure, and is prevented by the administration of topical corticosteroids. Interleukin-4 (IL-4), IL-5, and IL-6 may have important roles in this process, and in vitro the gene transcription for each of these cytokines is inhibited by corticosteroids. In this study we have therefore investigated the effect of seasonal allergen exposure on the expression of immunoreactivity for IL-4, IL-5, and IL-6 in nasal mucosal biopsies, and the effect of regular prophylactic treatment with the topical corticosteroid, fluticasone propionate. Following a nasal mucosal biopsy out of season, patients were randomized double-blind to receive 6 wk of treatment during the pollen season with either topical fluticasone nasal spray (200 micrograms daily) or matching placebo. Each subject underwent a repeat nasal biopsy at the end of the 6-wk treatment period. Seasonal increases in epithelial eosinophils (p = 0.046), submucosal eosinophils (p = 0.001), and epithelial mast cells (p = 0.055) occurred in the placebo--but not the fluticasone-treated patients. Submucosal mast cell numbers did not change in either group. Immunoreactivity for IL-4 and IL-6 was localized predominantly to mast cells while IL-5 was found in both mast cells and eosinophils. Numbers of IL-4+ cells in the nasal submucosa were significantly suppressed by treatment with fluticasone (p = 0.0003 for monoclonal antibody [mAb] 3H4, p = 0.041 for mAb 4D9). In contrast, fluticasone treatment failed to influence the number of IL-5 and IL-6 immunoreactive cells.(ABSTRACT TRUNCATED AT 250 WORDS)
1073-449X
1900-1906
Bradding, P.
39990c99-3c21-44b6-b1f7-084eddf29722
Feather, I.H.
85baeb57-711f-4ac1-91dc-1f6949170dfe
Wilson, S.J.
21c6875d-6870-441b-ae7a-603562a646b8
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Howarth, P.H.
ff19c8c4-86b0-4a88-8f76-b3d87f142a21
Bradding, P.
39990c99-3c21-44b6-b1f7-084eddf29722
Feather, I.H.
85baeb57-711f-4ac1-91dc-1f6949170dfe
Wilson, S.J.
21c6875d-6870-441b-ae7a-603562a646b8
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Howarth, P.H.
ff19c8c4-86b0-4a88-8f76-b3d87f142a21

(1995) Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. American Journal of Respiratory and Critical Care Medicine, 151 (6), 1900-1906. (doi:10.1164/ajrccm.151.6.7767538). (PMID:7767538)

Record type: Article

Abstract

Seasonal allergic rhinitis is characterized by the development of nasal mucosal inflammation in response to natural allergen exposure, and is prevented by the administration of topical corticosteroids. Interleukin-4 (IL-4), IL-5, and IL-6 may have important roles in this process, and in vitro the gene transcription for each of these cytokines is inhibited by corticosteroids. In this study we have therefore investigated the effect of seasonal allergen exposure on the expression of immunoreactivity for IL-4, IL-5, and IL-6 in nasal mucosal biopsies, and the effect of regular prophylactic treatment with the topical corticosteroid, fluticasone propionate. Following a nasal mucosal biopsy out of season, patients were randomized double-blind to receive 6 wk of treatment during the pollen season with either topical fluticasone nasal spray (200 micrograms daily) or matching placebo. Each subject underwent a repeat nasal biopsy at the end of the 6-wk treatment period. Seasonal increases in epithelial eosinophils (p = 0.046), submucosal eosinophils (p = 0.001), and epithelial mast cells (p = 0.055) occurred in the placebo--but not the fluticasone-treated patients. Submucosal mast cell numbers did not change in either group. Immunoreactivity for IL-4 and IL-6 was localized predominantly to mast cells while IL-5 was found in both mast cells and eosinophils. Numbers of IL-4+ cells in the nasal submucosa were significantly suppressed by treatment with fluticasone (p = 0.0003 for monoclonal antibody [mAb] 3H4, p = 0.041 for mAb 4D9). In contrast, fluticasone treatment failed to influence the number of IL-5 and IL-6 immunoreactive cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text not available from this repository.

More information

Published date: June 1995

Identifiers

Local EPrints ID: 190961
URI: http://eprints.soton.ac.uk/id/eprint/190961
DOI: doi:10.1164/ajrccm.151.6.7767538
ISSN: 1073-449X
PURE UUID: 16cf0200-332e-44f6-9f75-caa9a314804d

Catalogue record

Date deposited: 20 Jun 2011 15:10
Last modified: 28 Jun 2018 16:31

Export record

Altmetrics

Contributors

Author: P. Bradding
Author: I.H. Feather
Author: S.J. Wilson
Author: S.T. Holgate
Author: P.H. Howarth

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×